Attralus secures investment to transform treatment for patients with systemic amyloidosis

Christel Deskins

Attralus secures investment to transform treatment for patients with systemic amyloidosis KNOXVILLE—Attralus, a biopharmaceutical company with technology licensed from the UT Research Foundation, announced it has secured $25 million in investment financing to work on transformative medicines to improve the lives of patients with systemic amyloidosis. Load Error By strategically […]